Klonopin (clonazepam) is from a class of medicines called benzodiazepines, which belong to the group called central nervous system (CNS) depressants. Clonazepam’s primary use is for seizures and panic attacks but it is sometimes used to treat tremor and occasionally used to manage pain or spasticity when other medicines don’t work.

Its mechanism of action is not fully understood, but it is believed that clonazepam has the capacity to enhance the activity of the major inhibitory neurotransmitter in the central nervous system, slowing it down.

Some of the side effects that clonazepam may cause are: drowsiness, problems with walking and coordination, dizziness, depression, fatigue and problems with memory.

Clonazepam has a black box warning (information that appears on a prescription drug’s label and is designed to call attention to serious or life-threatening risks) concerning use with same class medicines, which may result in profound sedation, breathing difficulties, depression, coma, and death.

Klonopin is also available as a generic medicine.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

 

Trial of Cannabis Derivatives in Treating MS Spasticity to Open in Canada

The Multiple Sclerosis Society of Canada and its partner, the Canadian Institutes of Health Research (CIHR), have invested CA$1.5 million to open a clinical trial that will investigate the potential of two cannabis derivatives — cannabidiol (CBD) and tetrahydrocannabinol (THC) — in treating spasticity (muscle stiffness) and other symptoms of multiple sclerosis (MS). The money, worth about […]

Osmotica Amends NDA for Arbaclofen ER to Treat MS Spasticity

Osmotica Pharmaceuticals has submitted an amended new drug application (NDA) to the U.S. Food and Drug Administration (FDA) requesting the approval of arbaclofen extended release (ER) tablets for the treatment of spasticity in people with multiple sclerosis (MS). Arbaclofen ER (brand name Ontinua), is an extended release formulation of arbaclofen, a compound similar to the muscle […]

Spasticity Scales May Not Reflect Sativex Benefits in MS Patients, Study Suggests

Sativex (nabiximols) eases spasticity-associated symptoms in multiple sclerosis (MS) patients, including those with no significant improvements in a validated spasticity scale, according to a large study from Italy. The findings support previous studies suggesting that spasticity scales may not be enough to evaluate patients’ responses to Sativex and to reflect the therapy’s overall benefits beyond spasticity itself. […]

Nimodipine Can Prevent Spasticity Following Spinal Cord Injury, Mouse Study Shows

Nimodipine, an approved medication to prevent brain damage caused by hemorrhage, can be used to prevent spasticity following a spinal cord injury, a mouse study shows. In addition to spinal cord injury, nimodipine may be a promising treatment for neurodegenerative disorders such as multiple sclerosis (MS) and amyotrophic lateral sclerosis, in which spasticity often develops, investigators noted. […]

MS Patients Find Cannabis Helpful for Easing Pain, Spasticity, Study Reports

About 85% of people with multiple sclerosis (MS) using cannabis find it to be helpful for pain, and 79% find it eases spasticity, a new study reports. The study, “Cannabis use in people with multiple sclerosis and spasticity: A cross-sectional analysis,” was published in the journal Multiple Sclerosis and Related Disorders. A previous review study that examined the […]

THC:CBD Oral Spray Sativex Provides Consistent Relief for Treatment-resistant MS Spasticity

Sativex (nabiximols), a THC:CBD oral spray, consistently relieves the pain and severity of treatment-resistant spasticity in multiple sclerosis (MS) patients, according to a recent study. An analysis of the Sativex as Add-on therapy Vs. further optimized first-line ANTispastics (SAVANT) study revealed that Sativex, used in conjunction with an anti-spasticity medication, provided strong and consistent relief from the symptoms and […]

I Am Beautifully Rare Despite SPMS

I have secondary progressive multiple sclerosis and I am rare. In honor of Rare Disease Day on Feb. 29, I honor myself. I honor you and anyone else with a rare disease. I have been asked if multiple sclerosis qualifies as a rare disease. It does if you have MS. I became rare on Nov. […]

Flowonix’s Prometra II Pump System Receives FDA Approval for Use with Intrathecal Baclofen

  The U.S. Food and Drug Administration (FDA) has granted approval to Flowonix Medical’s Prometra II Programmable Pump System for use with intrathecal baclofen for the treatment of spasticity across numerous conditions, including multiple sclerosis. Intrathecal baclofen — sold as Gablofen by Piramal, Lioresal by Saol Therapeutics, and also in generic formulations – is administered via an injection into […]

Sativex, Cannabis Extract for MS Spasticity, Now Available to Select Patients in England

The cannabis sativa plant extract Sativex is a cost-effective therapy for spasticity in multiple sclerosis (MS) and can be offered to patients in England needing it on at least a monthlong trial basis, the National Institute for Health and Care Excellence (NICE) said in issuing a final recommendation on the treatment. This decision reverses a previous draft guidance that […]